Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced the PRECISION Registry, an ongoing study aimed at collecting data on the patterns of use, safety and effectiveness in the delivery and manipulation of percutaneous coronary intervention (PCI) devices.
Sunshine Heart, Inc. (Nasdaq:SSH) announced today the first patient implant in the Company's U.S. pivotal trial, COUNTER HF. The COUNTER HF study is a prospective, randomized, multi-center, controlled trial that will evaluate the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure.
A world’s first electronic smart pump which aims to increase the survival chances of victims of chronic heart failure is being developed by researchers at Nottingham Trent University and Nottingham University Hospitals NHS Trust. The smart aortic graft would be implanted into a removed section of the aorta.
On this episode of The Pulse, brought to you by MDT TV, we’re removing brain tumors with robots, using MetaboShield to help obesity, regenerating heart tissue, and pairing glucometers with smartphones for ease of use.
El Camino Hospital Enrolls Second Patient in Global Clinical Trial Evaluating the Medtronic CoreValve® System in Intermediate Risk Patients with Aortic Valve DiseaseSeptember 11, 2013 3:38 pm | by Business Wire | News | Comments
El Camino Hospital, in partnership with the Taft Center for Clinical Research and the Fogarty Clinical Research Institute, both a part of the Fogarty Institute for Innovation, announced today that it has enrolled its second patient in a global clinical trial comparing the Medtronic CoreValve® System with surgical aortic valve replacement in patients with severe aortic stenosis who are at intermediate risk for open-heart surgery.
Any time a disruptive technology comes along, prior generations of similar technologies are impacted. In the consumer market, customers generally adopt new technology rapidly if the price is right. For higher-value equipment, though, prior generations may find a new lease on life while customers wait until new technology price points come down.
W. L. Gore & Associates (Gore) today announced that the US Food and Drug Administration (FDA) has approved the Conformable GORE® TAG® Thoracic Endoprosthesis for endovascular repair of acute and chronic Type B dissections of the descending thoracic aorta.
SynCardia Systems, Inc. announced today that Matthew Green, the UK's 1st patient to be discharged with the SynCardia temporary Total Artificial Heart, has been successfully bridged to transplant after almost two years of support. Green, his wife and their 7-year-old son celebrated his new beginning with a holiday.
CardiacAssist announced the launch of the Protek17 Arterial Cannula, a key component of the TandemHeart temporary circulatory support platform used to rest the heart and circulate blood for patients with severe cardiac dysfunction. Protek17 is designed for improved patient safety and ease of use...
Whole-body MRI may serve as a valuable noninvasive tool for assessing the risk of heart attack and stroke in diabetic patients, according to a new study published online in the journal Radiology. Diabetes is a metabolic disease characterized by an increased concentration of glucose in the blood.
The famed Framingham Heart Study lost 40% of its budget to sequestration, which means layoffs and closures are on the way for the nation's longest-running cardiovascular disease trial. The study lost $4 million of its annual $9 million budget thanks to automatic funding cuts that took effect amid federal sequestration...
European Launch of New Version of Codman Neuro’s Revive SE Thrombectomy Device for Treatment of Acute Ischemic StrokeSeptember 9, 2013 2:06 pm | by Codman Neuro | News | Comments
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, announced the European launch of the REVIVE™ SE Thrombectomy Device, a next generation clot removal device offering enhanced navigation through the cerebral vasculature and rapid restoration of blood flow to the brain after an ischemic stroke.
Once-rejected CardioMEMs will get another shot at FDA approval for its Champion implantable heart failure monitoring systems when the agency's Circulatory System Devices Panel convenes next month, according to a notice in the Federal Register.
A team of scientists at Karolinska Institutet and Harvard University has taken a major step towards treatment for heart attack, by instructing the injured heart in mice to heal by expressing a factor that triggers cardiovascular regeneration driven by native heart stem cells.
Intelomed, Inc., a developer of noninvasive medical devices and technology for monitoring cardiovascular stability, today announced it has secured $4 million in funding from new and existing shareholders through the sale of its Series A-1 Common Preferred stock.
Keystone Heart, a leader in the development of cerebral protection devices for interventional cardiology and cardiac surgery procedures, announced today that its TriGuardT Cerebral Protection Device has received CE Marking, enabling the company to commercially market the TriGuard in Europe and other territories.
Meeting Announcement: October 8-9, 2013 Circulatory System Devices Panel of the Medical Devices Advisory CommitteeSeptember 9, 2013 12:00 am | by U.S. Food & Drug Administration | News | Comments
On both days the committee will discuss, make recommendations, and vote on devices indicated for use in patients with heart failure (HF). On October 8, 2013, the committee will discuss, make recommendations, and vote on information related to the premarket approval application regarding the expansion of indications supported by the BLOCK HF trial...
A slow heart rhythm puts patients at risk of early death, but a cardiac implant may help reset those odds, according to a Dutch study presented this week at the European Society of Cardiology Congress in Amsterdam. A study of pacemakers in 23 Dutch hospitals found that devices implanted to treat slow heart rhythm helped restore normal life expectancy.
Pure cardiac muscle cells, ready to transplant into a patient affected by heart disease. That’s a goal for many cardiology researchers working with stem cells. Having a pure population of cardiac muscle cells is essential for avoiding tumor formation after transplantation, but has been technically challenging.
Four patients in Kuala Lumpur, Malaysia were successfully treated with CardioKinetix's catheter-based Parachute ventricular partitioning device, the Menlo Park, Calif.-based firm announced late last month. The Parachute device is a minimally invasive catheter-based treatment which separates damaged heart muscle from healthy tissue...
Abbott announced today promising preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack.
A University of Iowa physiologist has a new technique to measure the stiffness of the aorta, a common risk factor for heart disease. And it can be as simple as measuring the pulse in your finger. The new procedure works by placing an instrument called a transducer on the finger or over the brachial artery...
Durham, N.C.-based Heart Imaging Technologies won a $2.5 million grant from the National Institutes of Health in support of efforts to build a "corelab of the future." HeartIT pioneered the WebPAX system, which the company calls the 1st FDA-approved zero-footprint medical imaging workstation.
Technology giant Philips awarded a 10-year contract for continuous access of its ultrasound devices to the cardiology department at Medical Center Leeuwarden, a teaching hospital in the Netherlands. The Dutch hospital will also receive training services and periodic structural upgrades as part of the deal.
Manny Villafaña, Chairman and Chief Executive Officer of Kips Bay Medical, Inc., a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS® Mesh, for use in coronary artery bypass grafting surgery (CABG), provided the following business update to Kips Bay shareholders and the financial community.